FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122343496> ?p ?o ?g. }

• W2122343496 endingPage "1013" @default.
• W2122343496 startingPage "1007" @default.
• W2122343496 abstract "BackgroundEpidermal growth factor receptor (EGFR) is overexpressed in 80%–90% of non-small-cell lung cancer (NSCLC). Matuzumab, a humanized immunoglobulin G1 (IgG1) anti-EGFR monoclonal antibody, blocks activation of EGFR. Paclitaxel and EGFR inhibitors have additive antitumour effects in vitro. This phase I study assessed the tolerability, pharmacokinetics and efficacy of the combination of matuzumab and paclitaxel in patients with advanced NSCLC.Materials and methodsEighteen chemotherapy-naïve (n = 9) or pretreated (n = 9) patients with stage IIIB or IV EGFR-positive NSCLC received weekly doses of matuzumab (100, 200, 400 or 800 mg) followed by paclitaxel 175 mg/m2 every 3 weeks. Toxicity was evaluated weekly and pharmacokinetics were measured during cycles 1 and 2.ResultsThe maximum planned matuzumab dose of 800 mg was achieved without reaching the maximum tolerated dose. Grade 4 neutropenia occurred in one of three patients at 800 mg but resolved within 1 week; five additional patients treated with 800 mg had no dose-limiting toxicity (DLT). Grade 1/2 acneiform skin rash in 14 patients was the most frequent matuzumab-related side-effect. There were no higher-grade adverse events. Grade 2 toxicities included pruritus (n = 2), bronchospasm (n = 1), fissures (n = 1), abdominal pain (n = 1) and hot flushes (n = 1). Paclitaxel was discontinued in four patients due to allergic reactions. Coadministration of paclitaxel did not alter matuzumab pharmacokinetics. Responses occurred in four of 18 patients and included one complete response.ConclusionsMatuzumab doses up to 800 mg weekly with paclitaxel 175 mg/m2 every 3 weeks are well tolerated, with no apparent drug interactions and with evidence of antitumor activity." @default.
• W2122343496 created "2016-06-24" @default.
• W2122343496 creator A5004950496 @default.
• W2122343496 creator A5018040656 @default.
• W2122343496 creator A5029130844 @default.
• W2122343496 creator A5056681317 @default.
• W2122343496 creator A5066624700 @default.
• W2122343496 creator A5068081109 @default.
• W2122343496 creator A5078383767 @default.
• W2122343496 creator A5087150696 @default.
• W2122343496 date "2006-06-01" @default.
• W2122343496 modified "2023-10-18" @default.
• W2122343496 title "A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)" @default.
• W2122343496 cites W1838340609 @default.
• W2122343496 cites W1874925441 @default.
• W2122343496 cites W1996654617 @default.
• W2122343496 cites W2016710415 @default.
• W2122343496 cites W2039633811 @default.
• W2122343496 cites W2043696829 @default.
• W2122343496 cites W2048686497 @default.
• W2122343496 cites W2075406660 @default.
• W2122343496 cites W2103384680 @default.
• W2122343496 cites W2127101185 @default.
• W2122343496 cites W2129432386 @default.
• W2122343496 cites W2133439571 @default.
• W2122343496 cites W2136228097 @default.
• W2122343496 cites W2137046569 @default.
• W2122343496 cites W2139248078 @default.
• W2122343496 cites W2139819066 @default.
• W2122343496 cites W2156670712 @default.
• W2122343496 cites W2206786835 @default.
• W2122343496 cites W2730858185 @default.
• W2122343496 cites W4252374499 @default.
• W2122343496 doi "https://doi.org/10.1093/annonc/mdl042" @default.
• W2122343496 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16533873" @default.
• W2122343496 hasPublicationYear "2006" @default.
• W2122343496 type Work @default.
• W2122343496 sameAs 2122343496 @default.
• W2122343496 citedByCount "90" @default.
• W2122343496 countsByYear W21223434962012 @default.
• W2122343496 countsByYear W21223434962013 @default.
• W2122343496 countsByYear W21223434962014 @default.
• W2122343496 countsByYear W21223434962015 @default.
• W2122343496 countsByYear W21223434962016 @default.
• W2122343496 countsByYear W21223434962017 @default.
• W2122343496 countsByYear W21223434962018 @default.
• W2122343496 countsByYear W21223434962019 @default.
• W2122343496 countsByYear W21223434962020 @default.
• W2122343496 countsByYear W21223434962021 @default.
• W2122343496 countsByYear W21223434962022 @default.
• W2122343496 countsByYear W21223434962023 @default.
• W2122343496 crossrefType "journal-article" @default.
• W2122343496 hasAuthorship W2122343496A5004950496 @default.
• W2122343496 hasAuthorship W2122343496A5018040656 @default.
• W2122343496 hasAuthorship W2122343496A5029130844 @default.
• W2122343496 hasAuthorship W2122343496A5056681317 @default.
• W2122343496 hasAuthorship W2122343496A5066624700 @default.
• W2122343496 hasAuthorship W2122343496A5068081109 @default.
• W2122343496 hasAuthorship W2122343496A5078383767 @default.
• W2122343496 hasAuthorship W2122343496A5087150696 @default.
• W2122343496 hasBestOaLocation W21223434961 @default.
• W2122343496 hasConcept C112705442 @default.
• W2122343496 hasConcept C121608353 @default.
• W2122343496 hasConcept C126322002 @default.
• W2122343496 hasConcept C143998085 @default.
• W2122343496 hasConcept C197934379 @default.
• W2122343496 hasConcept C2776256026 @default.
• W2122343496 hasConcept C2776694085 @default.
• W2122343496 hasConcept C2777063308 @default.
• W2122343496 hasConcept C2777292972 @default.
• W2122343496 hasConcept C2778375690 @default.
• W2122343496 hasConcept C2778570526 @default.
• W2122343496 hasConcept C2779438470 @default.
• W2122343496 hasConcept C71924100 @default.
• W2122343496 hasConcept C90924648 @default.
• W2122343496 hasConcept C98274493 @default.
• W2122343496 hasConceptScore W2122343496C112705442 @default.
• W2122343496 hasConceptScore W2122343496C121608353 @default.
• W2122343496 hasConceptScore W2122343496C126322002 @default.
• W2122343496 hasConceptScore W2122343496C143998085 @default.
• W2122343496 hasConceptScore W2122343496C197934379 @default.
• W2122343496 hasConceptScore W2122343496C2776256026 @default.
• W2122343496 hasConceptScore W2122343496C2776694085 @default.
• W2122343496 hasConceptScore W2122343496C2777063308 @default.
• W2122343496 hasConceptScore W2122343496C2777292972 @default.
• W2122343496 hasConceptScore W2122343496C2778375690 @default.
• W2122343496 hasConceptScore W2122343496C2778570526 @default.
• W2122343496 hasConceptScore W2122343496C2779438470 @default.
• W2122343496 hasConceptScore W2122343496C71924100 @default.
• W2122343496 hasConceptScore W2122343496C90924648 @default.
• W2122343496 hasConceptScore W2122343496C98274493 @default.
• W2122343496 hasIssue "6" @default.
• W2122343496 hasLocation W21223434961 @default.
• W2122343496 hasLocation W21223434962 @default.
• W2122343496 hasOpenAccess W2122343496 @default.
• W2122343496 hasPrimaryLocation W21223434961 @default.
• W2122343496 hasRelatedWork W1990197915 @default.
• W2122343496 hasRelatedWork W2087016115 @default.

• next